Saturday, February 04, 2012

Genitourinary Cancer

CA 184-043
A Randomized, Double-Blind, Phase 3 Trial Comparing Ipilimumab vs. Placebo Following Radiotherapy in Subjects with Castration Resistant Prostate Cancer That Have Received Prior Treatment with Docetaxel
CALGB-90203	Lead group: CALGB
A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer
CALGB-C90601
A Randomized Double-Blinded Phase III Study comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma.
CALGB 90802
A Randomized Phase III Trial Comparing Everolimus plus Placebo verses Everolimus plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment with Tyrosine Kinase Inhibitor (TKI).

We participate in many NCI sponsored trials. Please feel free to contact Leann Ross at (304) 399-6617 or leann.ross@chhi.org or Barbara Payne at (304) 399-6637.

For more information about the clinical trials listed please go to http://www.clinicaltrials.gov.